Methods of inhibiting complement C4 activation with anti-complement C1s antibodies
First Claim
Patent Images
1. A method of inhibiting activation of complement component C4 in an individual having cold agglutinin disease (CAD), the method comprising administering to the individual a pharmaceutical composition comprising:
- a pharmaceutically acceptable excipient suitable for administration to a human; and
a humanized antibody that binds complement C1s protein and comprises light chain complementarity determining regions (CDRs) of an antibody light chain variable region comprising amino acid sequence SEQ ID NO;
7 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO;
8.
2 Assignments
0 Petitions
Accused Products
Abstract
The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
-
Citations
13 Claims
-
1. A method of inhibiting activation of complement component C4 in an individual having cold agglutinin disease (CAD), the method comprising administering to the individual a pharmaceutical composition comprising:
-
a pharmaceutically acceptable excipient suitable for administration to a human; and a humanized antibody that binds complement C1s protein and comprises light chain complementarity determining regions (CDRs) of an antibody light chain variable region comprising amino acid sequence SEQ ID NO;
7 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO;
8. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
Specification